Two recently-approved CAR-T therapies for lymphoma, Bristol Myers Squibb Company’s Breyanzi and Gilead Sciences, Inc.’s Tecartus, face challenges in getting approval for supplemental Medicare reimbursement as novel agents because their indications could be considered the same or similar to older CAR-Ts.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?